DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Mease PJ, Chohan S, Fructuoso FJG. et al.
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis [abstract].
Arthritis Rheumatol 2019;
71 (Suppl. 10) 78-79
DOI: 10.1136/annrheumdis-2019-eular.8669.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.